Alexion To Pay $25M To Settle Soliris Suit
Biopharmaceutical firm Alexion Pharmaceuticals Inc. has agreed to pay $25 million to PDL BioPharma Inc. as part of a licensing deal that resolves PDL's patent infringement suit over Alexion's blood disorder...To view the full article, register now.
Already a subscriber? Click here to view full article